121,510 Shares in Ultragenyx Pharmaceutical Inc. $RARE Purchased by Cubist Systematic Strategies LLC

Key Points

• Cubist Systematic Strategies LLC has made a significant investment in Ultragenyx Pharmaceutical, purchasing 121,510 shares valued at approximately $4.4 million, marking a new position in the company.
• Several hedge funds have significantly increased their stakes in Ultragenyx, with notable increases from Graham Capital Management (34.4%) and Magnetar Financial (64.4%) during Q1.
• Ultragenyx recently reported earnings of ($1.17) EPS for the quarter, beating estimates, and saw a 13.2% increase in revenue, totaling $166.5 million compared to the prior year.

Cubist Systematic Strategies LLC purchased a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 121,510 shares of the biopharmaceutical company's stock, valued at approximately $4,400,000. Cubist Systematic Strategies LLC owned about 0.13% of Ultragenyx Pharmaceutical as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Stifel Financial Corp increased its position in shares of Ultragenyx Pharmaceutical by 13.5% during the fourth quarter. Stifel Financial Corp now owns 23,796 shares of the biopharmaceutical company's stock worth $1,001,000 after buying an additional 2,835 shares during the period. Knott David M Jr acquired a new stake in shares of Ultragenyx Pharmaceutical during the first quarter worth $1,738,000. Squarepoint Ops LLC acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth $3,702,000. BOKF NA increased its position in shares of Ultragenyx Pharmaceutical by 5.0% during the fourth quarter. BOKF NA now owns 7,976 shares of the biopharmaceutical company's stock worth $336,000 after buying an additional 382 shares during the period. Finally, Ameriprise Financial Inc. increased its position in shares of Ultragenyx Pharmaceutical by 8.4% during the fourth quarter. Ameriprise Financial Inc. now owns 13,396 shares of the biopharmaceutical company's stock worth $564,000 after buying an additional 1,039 shares during the period. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director directly owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.50% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Trading Down 0.5%

Shares of RARE traded down $0.16 during trading hours on Wednesday, reaching $31.34. 325,251 shares of the stock traded hands, compared to its average volume of 1,293,500. The stock has a fifty day simple moving average of $30.20 and a 200 day simple moving average of $34.63. Ultragenyx Pharmaceutical Inc. has a 52 week low of $25.81 and a 52 week high of $60.37. The company has a market cap of $3.02 billion, a price-to-earnings ratio of -5.65 and a beta of 0.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating analysts' consensus estimates of ($1.27) by $0.10. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. During the same period last year, the firm earned ($1.52) earnings per share. The firm's revenue was up 13.2% on a year-over-year basis. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. Analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RARE has been the subject of several recent analyst reports. Morgan Stanley decreased their price objective on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, July 14th. Canaccord Genuity Group reduced their price target on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a report on Friday, August 8th. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday. William Blair began coverage on shares of Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 price target for the company. Finally, Wedbush reduced their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, July 14th. Eleven equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.